BACKGROUND: Psoriasis, a chronic inflammatory disease associated with an accelerated risk of myocardial infarction, provides an ideal human model to study inflammatory atherogenesis in vivo. We hypothesized that the increased cardiovascular risk observed in psoriasis would be partially attributable to an elevated subclinical coronary artery disease burden composed of noncalcified plaques with high-risk features. However, inadequate efforts have been made to directly measure coronary artery disease in this vulnerable population. As such, we sought to compare total coronary plaque burden and noncalcified coronary plaque burden (NCB) and high-risk plaque (HRP) prevalence between patients with psoriasis (n=105), patients with hyperlipidemia eligible for statin therapy under National Cholesterol Education Program-Adult Treatment Panel III guidelines (n=100) who were ≈10 years older, and healthy volunteers without psoriasis (n=25).
A therosclerosis is an inflammatory disorder. 1 Psoriasis, a chronic inflammatory skin disease associated with increased cardiovascular risk, provides a clinical human model to study inflammatory atherogenesis. Patients with psoriasis experience myocardial infarction at younger ages than patients without psoriasis. 2, 3 This accelerated cardiovascular risk is most evident in adults <50 years of age with psoriasis, 3 is not accurately captured by traditional risk assessment, 4 and is likely attributable to an increased burden of subclinical coronary artery disease (CAD) in these patients with psoriasis. 5, 6 However, to date, inadequate efforts have been made to directly measure CAD in this vulnerable population before having cardiovascular events.
Coronary computed tomography angiography (CCTA) provides a high-quality, noninvasive imaging modality to assess 7 and quantify both total (TB) and noncalcified (NCB) burden of coronary plaque. 8 In addition, it provides a reliable tool to identify rupture-prone, high-risk coronary atherosclerotic plaques (HRPs), 9, 10 which have been associated with prospective cardiovascular events. 9 Indeed, lipid-rich plaques contain a higher density of macrophage content 11 and are more inflammatory with a higher expression of inflammatory cytokines. Other inflammatory disease states, including HIV disease, have been associated with increased noncalcified plaque and high-risk plaque features. 12, 13 Patients with psoriasis are younger when they experience their first cardiovascular event 3 and, as such, have lower Framingham Risk Scores.
14 At present, statins are the most validated drugs for primary and secondary cardiovascular prevention. 15 However, given the impact of age on statin recommendations, patients with psoriasis usually do not meet criteria for statins. Before release of the recent American College of Cardiology/ American Heart Association guidelines for statin recommendations, 16 the National Cholesterol Education Program-Adult Treatment Panel III guidelines 17 were used to decide eligibility for statin therapy in patients who were deemed at risk for future cardiovascular events. This group of patients represents a comparator of interest for patients with psoriasis to understand the prevalence of vascular disease because a statin-eligible group of patients with hyperlipidemia represents a common, already identified group at risk for future cardiovascular events.
Given the accelerated risk of myocardial infarction seen in psoriasis, the goal of our study was to compare coronary plaque burden, both TB and NCB, and the presence of HRP assessed by CT angiography between patients with psoriasis and a comparator cohort preselected to be at increased traditional risk-namely, patients with hyperlipidemia eligible for statin therapy under the National Cholesterol Education ProgramAdult Treatment Panel III guidelines, matched to be >10 years older than patients with psoriasis. 18, 19 In addition, we followed a consecutive sample of patients with psoriasis (n=50) to investigate how modulation of skin disease severity over a 1-year follow-up period was associated with longitudinal changes in coronary plaque burden. We hypothesized that (1) patients with psoriasis would have greater NCB than patients with hyperlipidemia and healthy volunteers (HV) without psoriasis, (2) patients with psoriasis would have a greater burden of HRP than HV and at least an equivalent burden as patients with hyperlipidemia, and (3) patients who experienced a longitudinal improvement in the severity of skin disease would not have progression in coronary burden compared with patients with poorly controlled skin disease. Such an investigation may provide unique insight into the elevated cardiovascular risk associated with this common inflammatory disorder and inform the natural history of inflammatory atherogenesis.
METHODS
Our study included 3 cohorts of participants all recruited at the National Institutes of Health Clinical Center, namely, patients with psoriasis (n=105), a hyperlipidemic cohort (eligible for statin therapy by National Cholesterol Education ProgramAdult Treatment Panel III guidelines and without psoriasis) (n=100), and HV who did not have psoriasis, or any other underlying inflammatory disease, matched by age and sex to the patients with psoriasis, henceforth the HV cohort (n=25). The psoriasis and HV cohorts were recruited starting from January 1, 2013, to October 31, 2015, whereas the hyperlipidemic cohort was recruited from September 30, 2010, to
Clinical Perspective
What Is New?
• In a deeply phenotyped cohort, psoriasis was associated with an increased presence of noncalcified coronary plaque and a similar prevalence of highrisk plaque compared with an older, hyperlipidemic population.
• In a consecutive sample of patients with psoriasis, improvement in skin disease severity was associated with an improvement in coronary plaque burden at 1-year follow-up.
What Are the Clinical Implications?
• Patients with psoriasis have similar coronary artery disease risk as patients with hyperlipidemia 1 decade older.
• As such, this young, vulnerable population should be screened earlier for cardiovascular disease and should be educated about their elevated risk.
• Further investigations should focus on the longitudinal impact of psoriasis treatment on high-risk plaque morphology, as well as the extent of cardiovascular risk mitigation in randomized trials.
Patients with psoriasis were stratified by decades of age, and because >90% were within 35 to 65 years of age, 4 to 5 HV were selected for each 5-year age range of patients with psoriasis between 35 and 65 years of age. Furthermore, because 62% of patients with psoriasis were males, we attempted to include similar proportion of males under the HV group. All patients underwent fasting blood draws for the assessment of the lipid panel, including total high-and lowdensity lipoprotein cholesterol, glucose, and high-sensitivity C-reactive protein levels. A dermatologist or physician evaluated all patients with psoriasis for the assessment of psoriasis skin disease severity measured as a psoriasis area severity index (PASI) score. Systemic-biological treatment was defined as the following drugs: methotrexate, anti-tumor necrosis factor, anti-interleukin (IL) 12/IL23, and anti-IL17. Plasma inflammatory biomarkers were assessed (Mesoscale Diagnostics) based on previously published methods. 20 Cholesterol efflux capacity measurement was performed using a validated ex vivo assay of J774 cholesterol-loaded macrophages as previously published. 18 All patients underwent CCTA on the same day as the blood draw using the same CT scanner (320-dectector row Aquilion ONE ViSION). All guidelines set forth by the National Institutes of Health Radiation Exposure Committee were followed. Scans were performed with retrospective gating at 120 kV, tube current of 750 to 850 mA, with a gantry rotation time of ≤420 ms. Image-acquisition characteristics included slice thickness of 0.75 mm and pitch 0.2 to 0.4. Coronary plaque burden adjusted for luminal attenuation was evaluated across each of the main coronary arteries using the dedicated software QAngio CT by previously described methods by a single blinded reader. 18, 21 Manual adjustment of inner lumen and outer vessel wall delineations were performed if needed. TB and NCB plaque volume indices, assessed as mm 2 , were calculated by dividing total vessel plaque volume by total vessel length and were attenuated for luminal intensity measures for accuracy. Test-retest reliability was analyzed using intraclass correlation coefficient (ICC) testing and demonstrated very good intraexaminer reliability (ICC=95%). In addition, ICC testing showed high ICC between 2 experienced readers (ICC=92%) in a subset of patients. All coronary segments with a diameter >2 mm were then analyzed by a single reader blinded to the patients' coronary plaque burdens for the presence of HRP features, defined as positive remodeling (remodeling index >1.10), low attenuation (<30 hounsfield units), or spotty calcification. 22 Positive remodeling was assessed visually in multiplanar reconstructed images in both short-and long-axis views of the vessel. Measurements of the outer vessel diameter were performed at the reader's discretion, and remodeling index >1.10 was defined as a positively remodeled plaque based on validated findings from the previously published literature. 9 If low-CT attenuation was visually observed within a noncalcified plaque, 3 region-ofinterest measurements (>0.5 mm 2 ) were placed. Mean CT attenuation within these regions-of-interest <30 HU was deemed low-attenuation plaque. 9, 10 Last, spotty calcification was defined by the presence of calcified plaque (HU >350) 23 with a diameter <3 mm in any direction, length of the calcification (measured in longitudinal direction of the vessel) <1.5 times the vessel diameter, and width (measured in the perpendicular direction to the vessel) <30% of the vessel diameter. 22 The patient was classified as having a high-risk plaque if any of these plaque features were present. Test-retest reliability for HRP evaluation was also assessed by 2 experienced readers and demonstrated similar results (ICC=92% for intraexaminer and ICC=90% for interexaminer).
Last, a consecutive sample of the first 50 recruited patients with psoriasis was followed for 1 year ( Figure I in the onlineonly Data Supplement). These patients underwent repeat blood tests, clinical assessment for skin disease severity, medication usage, and CCTA scans with the same scanner for a repeat quantification of coronary plaque burdens by the same reader at 1-year follow-up visits.
Statistical Analyses
Psoriasis and HV cohorts were matched by age and sex. The hyperlipidemic cohort was recruited separately. Skewness and kurtosis measures were considered to assess normality. Continuous data were summarized as mean±SD for parametric variables and as median with interquartile range for nonparametric variables. Categorical variables were reported as percentages. Student t test for parametric data and Mann-Whitney U test for nonparametric data were performed for continuous variable comparisons, and Pearson's χ 2 tests were performed for categorical variables. Univariable logistic regression analyses were performed to assess crude associations between the prevalence of HRP and study variables. Moreover, to compare the prevalence of HRP in psoriasis and hyperlipidemic to that in HV, we utilized multivariable logistic regression analyses. In these models, we adjusted for covariates including traditional cardiovascular risk factors such as age, sex, atherosclerotic cardiovascular disease (ASCVD) 10-year risk, 24 body mass index (BMI), glucose, and statins. Residual plots were generated subsequent to the regression models confirming that the data were normally distributed. Odds ratios with 95% confidence intervals and corresponding P values were reported for all the models. Furthermore, for patients with longitudinal follow-up, we assessed continuous variables either by paired t test (parametric data) or Wilcoxon signed-rank test (nonparametric data). Categorical variables were assessed over 1 year by χ 2 test. Multivariable linear regression analyses were performed to assess the relationship between change in coronary plaque burden and change in PASI score. Standardized β-coefficient values were reported for these analyses. Standardized β-coefficient represents the number of standard deviation change in coronary plaque burden per 1 standard deviation change in PASI score.
We hypothesized a 20% difference in NCB between patients with psoriasis and controls. Thus, our sample size had >90% power to detect this difference significantly. We used previously published values of NCB for patients with psoriasis 18 and HV. 25 STATA-12 was utilized for all statistical analysis. P values <0.05 were considered significant.
RESULTS

Characteristics of the Study Groups
We summarize the demographic and clinical characteristics of our study cohorts in Table 1 . A total of 230 individuals participated in the study. Patients with psoriasis were middle age (mean±SD=50.4±12.6) and had moderate-to-severe skin disease (PASI Score, med. [interquartile range]: 5.7 [3] [4] [5] [6] [7] [8] [9] [10] ), whereas the mean age in patients with hyperlipidemia was 61.2 years (SD=3.5) and that in HV was 47.7 (SD=9.8). A male predominance (psoriasis: 61%, hyperlipidemic: 54%, HV: 76%) among all 3 groups was evident. Patients with psoriasis had a greater mean BMI (psoriasis: 29.9±6.2 versus hyperlipidemic: 27.5±5.0, P=0.001), whereas a higher prevalence of dyslipidemia and a greater use of lipid-lowering therapies occurred in the hyperlipidemic group (psoriasis: 33% versus hyperlipidemic: 81%). It is important to note that the hyperlipidemic group was at significantly greater cardiovascular risk than patients with psoriasis by both Framingham risk score (median 
Coronary Plaque Burden Quantification and Plaque Characterization in the Study Groups
Quantitative coronary plaque burden evaluation was performed in 3380 of 3450 (98%) Figure. This figure demonstrates a baseline HRP in a patient with psoriasis who, during longitudinal follow-up, had an acute myocardial infarction and was found to have a culprit lesion on catheterization corresponding to the previously identified HRP in the right posterior descending artery.
Greater Noncalcified Burden Is Associated With Increased Prevalence of High-Risk Plaque in Patients With Psoriasis
To better understand the driving factors of coronary artery disease in psoriasis, we compared the demographic and clinical characteristics of patients with psoriasis by stratifying the psoriasis cohort based on the median value of NCB ( 
ORIGINAL RESEARCH ARTICLE
Association Between Prevalence of High-Risk Plaque and Study Variables
We then conducted univariate logistic regression analyses to examine the relationships between traditional cardiometabolic risk factors and the presence of HRP (Table  II in 
Psoriasis Had a Strong Association With High-Risk Plaques to a Similar Extent as Seen in High-Risk Patients With Hyperlipidemia
To evaluate the extent of HRP in the psoriasis and hyperlipidemic groups compared with the HV group, we subsequently conducted multivariable logistic regression analyses (Table 4) . Patients with both psoriasis and hyperlipidemia had an elevated prevalence of HRP compared with the HV group in unadjusted analyses (psoriasis: OR, 6.0; 95% CI, 1.3-26.9 P=0.019; hyperlipidemic: OR, 7.1; 95% CI, 1.6-31.6; P=0.011). Among Last, to understand the potential role of psoriasis skin disease severity in progression of CAD, we followed the first 50 participants with psoriasis in our cohort for 1 year. Demographic and clinical characteristics of these patients at baseline and 1-year follow-up, stratified by an improvement versus worsening in skin inflammation, are presented in Table 5 . Furthermore, the specific biological treatment modalities that the patients received are elaborated ( Figure. High-risk plaque in a patient with psoriasis who was subsequently found to be a culprit for an ST-elevation myocardial infarction during follow-up. Baseline high-risk plaque characteristics in a patient with psoriasis who during longitudinal follow-up was found to have an acute ST-elevation myocardial infarction, with a catheterization-identified culprit lesion corresponding to the previously identified coronary computed-tomography angiography high-risk plaque. A, 3-Dimensional reconstruction of baseline coronary computed-tomography angiography demonstrating stenosed vessel in coronary computed-tomography angiography. B, Planar reconstruction of vessel demonstrating high-risk plaque. C, Clinical catheterization identified culprit lesion (yellow arrow). D, Color-coded curved multiplanar reconstruction (green, vessel lumen; blue, noncalcified plaque component; yellow, calcified plaque component). E and F, Cross-sectional images. The plaque is only partially calcified, showing spotty calcification and some positive remodeling. Stenosis was graded as moderate-severe. 95% CI, 2.00-4.47 versus 1-year: β=2.17; 95% CI, 1.76-2.48; P=0.005), IL1-β (baseline: β=0.07; 95% CI, 0.07-0.40 versus 1-year: β=0.04; 95% CI, 0.00-0.38; P<0.0001), and monocyte chemotactic protein-1 (baseline: β=96.95; 95% CI, 60.89-128.55 versus 1-year: β=64.99; 95% CI, 48.83-82.67; P<0.0001). However, adjustment for these biomarkers did not change the association between reduction in PASI score and improvement in coronary plaque burden (Table 6) . Last, in patients who did not have improvement in their skin disease, we did not observe a reduction in these proteins (Table 5) .
DISCUSSION
In this study, we demonstrate several important novel findings: (1) patients with psoriasis have an increased coronary NCB, assessed by CCTA, compared with a hyperlipidemic cohort with a mean age >10 years older; (2) the prevalence of HRP was similar between patients with psoriasis and hyperlipidemia and was ≈6 times greater than that observed in HV despite patients with psoriasis being at significantly lower traditional cardiovascular risk than patients with hyperlipidemia and equivalent risk as HV; (3) patients with psoriasis with an ORIGINAL RESEARCH ARTICLE increased NCB had a significantly higher prevalence of HRP compared with those patients with a lower NCB; (4) among consecutive patients with psoriasis followed for 1 year, reduction in skin disease severity was associated with an improvement in NCB. Collectively, these findings provide unique insight into the epidemiological association of psoriasis and increased cardiovascular risk, and they support a role for a reduction of remote systemic inflammation in modulating CAD.
Inflammation is increasingly recognized as a driver of atherosclerotic cardiovascular diseases. 1 Inflammatory mediators are known to play a critical role in each stage of atherogenesis, from initial endothelial cell dysfunction 26 to ultimate atherosclerotic plaque rupture. 27 Conversely, anti-inflammatory therapies, including statins, are commonly used for primary and secondary cardiovascular prevention. 16 Psoriasis, a chronic inflammatory immune disease associated with increased cardiovascular risk, thus provides a useful clinical model to study the role of systemic inflammation in atherogenesis. Evidence suggests that psoriasis is linked to baseline cardiometabolic dysfunction, including high insulin resistance, 28 poor high-density lipoprotein function, 18 and obesity. 29 Patients with psoriasis are at significantly elevated relative risk for myocardial infarction. 3 However, the increased risk noted in this common inflammatory condition is not captured by traditional risk assessment 4 and persists beyond adjustment for these factors.
CCTA is a reliable, noninvasive imaging modality that allows for quantification of total and noncalcified coronary plaque volume and characterization of coronary plaque content. Prior work demonstrates that TB and NCB correlate with traditional measures of cardiovascular risk 30 and predict prospective cardiovascular events in patients without inflammatory conditions. 25 We demonstrated that patients with psoriasis and hyperlipidemia had increased TB compared to with HV. Furthermore, patients with psoriasis had equivalent TB as patients with hyperlipidemia but greater NCB than both HV and patients with hyperlipidemia despite being 10 years younger and at lower traditional cardiovascular risk than patients with hyperlipidemia. Because noncalcified coronary plaques are frequently identified as culprit lesions in myocardial infarction, 31 our results are consistent with the elevated cardiovascular event rate noted in young patients with psoriasis 2, 3 and provide an important advance in the understanding of the epidemiological association. Furthermore, these findings that inflammation may drive this NCB are in line with a recent study demonstrating that HIV is associated with higher NCB compared with HV. 13, 32 Recent literature has identified particular coronary plaque characteristics associated with plaque rupture and future cardiovascular events. 9, 10 Our study indicates that patients with psoriasis and hyperlipidemia have an increased prevalence of HRP compared with HV but a similar prevalence of HRP compared with one another. The increased prevalence of HRP in psoriasis was independent of traditional cardiovascular risk factors, suggesting a link between this inflammatory condition and HRP. The prevalence of HRP among patients with hyperlipidemia was comparable to the prevalence seen in a prior study, which defined HRP as spotty calcification, low attenuation, positive remodeling, and napkin ring sign positivity. 10 Such prevalence is greater than that seen in a recent landmark study assessing cardiovascular outcome prediction by HRP 9 ; however, this study defined HRP as positive remodeling and low attenuation alone. Our findings that younger patients with psoriasis with lower traditional cardiovascular risk have an equal prevalence of HRP compared with higher risk patients with hyperlipidemia are thus compelling. Indeed, prior studies have demonstrated that increased vascular inflammation by fluorodeoxyglucose positron emission tomography/CT is associated with HRP in HIV, 12 and HRP have increased inflammatory positron emission tomography uptake. 33 Given the known association between psoriasis and elevated vascular inflammation, 20 our findings are thus consistent with the hypothesized relationship between inflammation and rupture-prone plaque formation.
Because higher NCB was associated with an increased prevalence of HRP, we followed a consecutive sample of patients with psoriasis in the cohort to understand how modulation of skin inflammation associated with the longitudinal progression of NCB. In this consecutive sample, patients with psoriasis who experienced a reduction in skin inflammation were noted to have an improvement in NCB at 1-year follow-up, independent of traditional cardiovascular risk. These results echo prior work that has revealed an association between psoriasis skin inflammation and cardiovascular risk 3 and suggests that anti-inflammatory treatment may mitigate such risk. [34] [35] [36] Because inflammation is a critical component of atherosclerosis pathophysiology, chronic inflammation in patients with psoriasis plays a role in the shared mechanisms driving accelerated atherosclerosis. Emerging concepts suggest that inflammatory cytokines such as tumor necrosis factor-α and ILs, which are well-known elements in the pathogenesis of atherosclerosis, 1 are also involved in the causal pathways of psoriasis. 37 Therefore, novel treatment modalities targeting these proinflammatory cytokines may have a favorable impact beyond ORIGINAL RESEARCH ARTICLE skin clearance in patients with psoriasis and may mitigate the risk of cardiovascular disease. It is interesting to note that, in our study, levels of monocyte chemotactic protein-1, tumor necrosis factor-α, and IL-1β decreased in blood at 1 year in those who improved their skin disease severity, which was also associated with an improvement in total and noncalcified coronary plaque. However, adjustment of these biomarkers in our final statistical model did not attenuate the association between a decrease in PASI score and a decrease in coronary plaque burden. This finding suggests that these proteins may not be the primary drivers of our observation of the association between reduction in skin diseases severity and improvement in coronary plaque burden. Our findings do support future efforts to broadly characterize immune cells and their protein products to dissect potential shared mechanistic links between psoriasis improvement and improvement in coronary plaque. A recent publication described a higher presence of calcified, mixed, and noncalcified plaque, compared with healthy controls, in arthritis patients with psoriasis. 38 Although this publication provided an important qualitative description of coronary plaque in psoriasis, our study extends these findings by providing quantitative analyses of coronary plaque by volume. To our knowledge, this study is the first to perform segmental quantification of coronary plaque burden in psoriasis and compare it to an older, at-risk group as well as an age-matched healthy group. Furthermore, our study characterized high-risk features of coronary plaque in an effort to understand the increased risk of acute myocardial infarction observed in patients with psoriasis. Last, longitudinal examination over 1 year in our study demonstrated that successful reduction of psoriatic skin disease was associated with an improvement in early, noncalcified coronary plaque burden. These findings in particular are of great interest because they suggest that early, noncalcified plaque may be reversible with careful anti-inflammatory therapy. Whether aggressive cardiovascular risk factor management will further improve noncalcified coronary plaque Standardized β coefficient for each model represents the number of standard deviation change in total or noncalcified burden per 1 standard deviation change in PASI score.
ASCVD indicates atherosclerotic cardiovascular disease 10-year risk; BMI, body mass index; CI, confidence interval; IL-1β, interleukin-1β; MCP-1, monocyte chemotactic protein-1; PASI, Psoriasis Area Severity Index; and TNF-α, tumor necrosis factor-α. burden is unknown. Future studies should focus on aggressive cardiovascular risk reduction in conjunction with anti-psoriatic therapy because larger benefits may be observed with more aggressive lipid, glucose, and blood pressure management.
Our study is limited by the small sample size; however, this study is the largest systematic characterization to date in patients with psoriasis and hyperlipidemia eligible for statin therapy. Moreover, a single blinded reader interpreted the CCTA scans for all the patients; however, good intra-and interexaminer reliability was present among a subset of patients whose scans were read by 2 separate readers. Furthermore, we had a disproportionately small cohort of HV; however, this group provided important comparator data in the context of the hyperlipidemic group. In addition, we had follow-up data available for a subset of patients for a short duration of follow-up of only 1 year, which is relatively short compared with published literature on coronary plaque natural history. However, we followed a consecutive sample to minimize any selection bias in longitudinal follow-up. Moreover, our consecutive sample of patients followed for improvement in skin disease to understand whether NCB improved was not stratified by treatment, nor was it randomized. Therefore, our study results should be interpreted with caution. Given the observational study design, the possibility of residual confounding cannot be excluded, although we attempted to adjust for sources of bias with the available data. Last, our study relied on a surrogate marker of coronary artery disease (CCTA) as the primary outcome instead of hard cardiovascular events. However, our goal was to understand the natural history before events in these groups. Future studies should focus on characterization of the natural history of high-risk plaque over longer periods of time and with specific therapies for psoriasis in larger sample sizes. Furthermore, a dedicated study of HV enrolled for longitudinal assessment of high-risk plaque should be performed to provide context to the natural history of such plaques in diseased populations. Ongoing studies are investigating the effect of anti-inflammatory therapies on vascular inflammation by fluorodeoxyglucose positron emission tomography/CT in psoriasis (URL: http:// www.clinicaltrials.gov. Unique identifier: NCT02187172, NCT02690701) but none in coronary plaque burden at this time. Similar randomized control trials should be performed for the longitudinal characterization of high-risk coronary plaque in psoriasis. Last, large epidemiological, prospective event trials should be performed to investigate the proposed association of systemic inflammation and increased cardiovascular events.
CONCLUSION
In conclusion, patients with psoriasis have an increased volume of noncalcified plaque burden compared with patients with hyperlipidemia who are at higher cardiovascular risk by traditional scores. In addition, we observed an equivalent prevalence of high-risk plaque between patients with psoriasis and an older hyperlipidemic comparator group eligible for statin therapy. Furthermore, modulation of remote skin inflammation associated with an improvement of noncalcified plaque burden in patients with psoriasis at 1-year follow-up, suggesting that control of remote inflammation may translate into reduction in CAD risk. We suggest that, based on our findings, screening for cardiovascular risk factors in patients with psoriasis, especially when it is severe, is warranted.
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